AI Software Analyzes Diffusion MRI Scans to Build Detailed Map of Brain's White Matter

Imeka’s (Sherbrooke, QC, Canada) Advanced Neuro Diagnostic Imaging (ANDI) quantitative imaging software extracts white matter bundles connecting the brain’s specific regions and conducts microstructure analysis along them. ANDI processes diffusion-weighted images utilizing reconstruction algorithms, such as modeling, tractography, and fiber bundling, to map the microstructural properties of the white matter. The software produces a DICOM-encapsulated PDF report that highlights the bundles showing significant deviations from the normative range and provides an exhaustive evaluation of both microstructural and macrostructural values of all the bundles. The ANDI-generated report equips healthcare experts, including radiologists and neurologists, with vital data on brain white matter to enhance their patient care efforts. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Imeka's ANDI imaging software.

"Many medical imaging tools involving AI have been cleared for use in the clinic in the past two years, which shows the strength and progression of the field. Imeka is pioneering AI in diffusion MRI-based white matter imaging to evaluate microstructural properties of white matter in greater detail than any other techniques," said Jean-René Bélanger, Chief Executive Officer at Imeka. "We are pleased to announce FDA 510(k) clearance of ANDI, our quantitative imaging software, and make the technology available to healthcare providers across the U.S. – which is going to have a major impact in brain disease management in the coming years. This also comes at a very crucial time with the announcement of the addition of two new CPT 3 codes by the AMA for quantitative brain MRI assessment, which we expect our clients to be able to get reimbursement from, starting in January 2024."

Related Links:
Imeka